DRUG RESISTANT IMMUNOTHERAPY FOR TREATMENT OF A CANCER

(19)

(11)

EP 2 496 244 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	08.11.2017 Bulletin 2017/45

(45)	Mention of the grant of the patent:
	12.04.2017 Bulletin 2017/15

(21)	Application number: 10827507.4

(22)	Date of filing: 29.10.2010

(51)

International Patent Classification (IPC):

A61K 38/16^(2006.01)
A61P 35/00^(2006.01)

A61K 38/17^(2006.01)

(86)	International application number:
	PCT/US2010/054608

(87)	International publication number:
	WO 2011/053750 (05.05.2011 Gazette 2011/18)

(54)	DRUG RESISTANT IMMUNOTHERAPY FOR TREATMENT OF A CANCER WIRKSTOFFRESISTENTE IMMUNTHERAPIE ZUR KREBSBEHANDLUNG IMMUNOTHÉRAPIE PHARMACORÉSISTANTE POUR LE TRAITEMENT D'UN CANCER

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

02.11.2009 US 257136 P

(43)	Date of publication of application:
	12.09.2012 Bulletin 2012/37

(60)	Divisional application:
	17165351.2

(73)	Proprietors:
	Emory University Atlanta, Georgia 30322 (US) Children's Healthcare of Atlanta, Inc. Atlanta, GA 30329 (US) The UAB Research Foundation Birmingham, AL 35294-0107 (US)

(72)	Inventors:
	SPENCER, H., Trent Marietta GA 30062 (US) DASGUPTA, Anindya Anderson, SC 29625 (US) LAMB, Lawrence, S. Birmingham, AL 35294 (US)

(74)	Representative: Hart, Deborah Mary et al
	Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL London WC1X 8NL (GB)

(56)

References cited: :

US-A- 6 071 512

SCHROEDER MARK A ET AL: "Forced expression of the IY mutant inosine monophosphate dehydrogenase II results in physiologically significant resistance to mycophenolic acid in vitro", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 108, no. 11, suppl, 1 June 2004 (2004-06-01), XP009171503, ISSN: 0006-4971
STEPHEN R MATTAROLLO ET AL: "Chemotherapy and zoledronate sensitize solid tumour cells to V[gamma]9V[delta]2 T cell cytotoxicity", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 56, no. 8, 31 January 2007 (2007-01-31), pages 1285-1297, XP019514181, ISSN: 1432-0851, DOI: 10.1007/S00262-007-0279-2
H T Spencer ET AL: "A gene transfer strategy for making bone marrow cells resistant to trimetrexate", Blood, 1 January 1996 (1996-01-01), pages 2579-2587, XP055073297, Retrieved from the Internet: URL:http://bloodjournal.hematologylibrary. org/content/87/6/2579.full.pdf#page=1&view =FitH [retrieved on 2013-07-29]
D. W. Mcmillin ET AL: "Complete Regression of Large Solid Tumors Using Engineered Drug-Resistant Hematopoietic Cells and Anti-CD137 Immunotherapy", Human Gene Therapy, 1 August 2006 (2006-08-01), pages 798-806, XP055073317, Retrieved from the Internet: URL:http://online.liebertpub.com/doi/pdf/1 0.1089/hum.2006.17.798 [retrieved on 2013-07-29]
RUPAL RAMAKRISHNAN ET AL: "Combined modality immunotherapy and chemotherapy: a new perspective", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 57, no. 10, 17 May 2008 (2008-05-17), pages 1523-1529, XP019624425, ISSN: 1432-0851
DOTTI G ET AL: "CURRENT STATUS OF GENETIC MODIFICATION OF T CELLS FOR CANCER TREATMENT", CYTOTHERAPY, ISIS MEDICAL MEDIA, OXFORD, GB, vol. 7, no. 3, 1 July 2005 (2005-07-01), pages 262-272, XP009060587, ISSN: 1465-3249, DOI: 10.1080/14653240510027217
CHINNASAMY DHANALAKSHMI ET AL: "Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3- bis(2-chloroethyl)-nitrosourea or temozolomide", HUMAN GENE THERAPY, vol. 15, no. 8, August 2004 (2004-08), pages 758-769, XP055073341, ISSN: 1043-0342
J. Jiang ET AL: "Treatment of Advanced Gastric Cancer by Chemotherapy Combined with Autologous Cytokine-induced Killer Cells", Anticancer Research, 1 January 2006 (2006-01-01), pages 2237-2242, XP055074346, Retrieved from the Internet: URL:http://ar.iiarjournals.org/content/26/ 3B/2237.full.pdf#page=1&view=FitH [retrieved on 2013-08-06]
DASGUPTA A. ET AL: 'Engineered drug resistant immunocompetent cells enhance tumor cell killing during a chemotherapy challenge' BIOCHEM. BIOPHYS.RES. COMMUN. vol. 391, no. 1, 01 January 2010, pages 170 - 175, XP008156422
NOWAK A.K. ET AL: 'Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors' CANCER RESEARCH vol. 63, 01 August 2003, pages 4490 - 4496, XP008156419
HERMANS I.F. ET AL: 'Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model' CANCER RESEARCH vol. 63, 01 December 2003, pages 8408 - 8413, XP008156423
HEIMBERGER A.B. ET AL: 'Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study' NEURO-ONCOLOGY vol. 10, 13 December 2008, pages 98 - 103, XP008156428

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).